Stereotaxis, Inc. (STXS) Earnings Call Transcripts

Stereotaxis, Inc.'s Latest Earnings Call - April 15, 2026

In the first quarter of fiscal year 2026, Stereotaxis, Inc. (STXS) announced the acquisition of Robocath, a strategic move aimed at enhancing its robotic capabilities in interventional cardiology and neuro interventions. The company expects approximately $2 million in annual revenue from the acquisition, with a focus on regulatory submissions for Robocath's next-generation system. Stereotaxis maintained its previous revenue guidance of $40 million for fiscal 2026, signaling confidence in its existing product portfolio while integrating Robocath's technology.

Reported metrics

Guidance from management

Stereotaxis expects to close the acquisition of Robocath in mid-2026 and anticipates approximately $2 million in annual revenue from the acquisition, with a focus on regulatory submissions for the next-generation system.

What management said

Sure. So can you give a first try and Philippe can add. I mean chronic total occlusions are one very, very clear one, then you have a range of times where you have to do angioplasty in more distal, more tortuous vessels and that's kind of a second room. Sometimes you have to do it at a bifurcation of vessels. That's probably a third group. And so I'd say those are 3 categories that are clear complex ones in the PCI s...

And you can look at the TAM for interventional cardiology and neuro interventions in various ways. I mean it's easily [indiscernible] plus medical device market, just the catheters used in those procedures. And so it's -- we're talking about very, very big fields. And when -- even if you look at just procedures that are 10% of those -- and it's obviously a very, very large market. So I think given our current vantage...

What analysts pressed on

Analysts expressed concerns about the integration of Robocath's technology with Stereotaxis' existing systems and the potential impact on cash burn and operating expenses. There were questions regarding the timeline for regulatory approvals and how the acquisition would affect the overall financial model.

Main topics on the call

• Acquisition of Robocath — Stereotaxis announced the acquisition of Robocath for an upfront payment of $20 million, with additional contingent payments of up to $25 million based on regulatory and commercial milestones. CEO David Fischel stated, "...
• Revenue Guidance Maintained — Stereotaxis reaffirmed its fiscal 2026 revenue guidance of $40 million, indicating stability in its financial outlook despite the new acquisition. Fischel noted, "We stick with our previous guidance," which reflects conf...
• Regulatory Strategy for Robocath — Management emphasized the importance of regulatory submissions for Robocath's next-generation system, which is currently in development. Fischel mentioned, "We expect regulatory approvals for both Imagine devices later t...
• Financial Impact of Acquisition — The acquisition is expected to be cash flow negative initially but is projected to become breakeven by the third year post-acquisition. Fischel stated, "We plan to close the acquisition in the middle of this year," sugge...

Read the full Stereotaxis, Inc. transcript (April 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 27 Stereotaxis, Inc. earnings call transcripts on record, spanning March 10, 2020 to May 12, 2026. Based on this history, Stereotaxis, Inc. reports quarterly. The most recent call on file is dated May 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

STXS

Exchange

NYSEAM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

27

First call

March 10, 2020

Most recent

May 12, 2026

Reporting cadence

quarterly